A NEW analysis of five clinical trials confirms that dupilumab significantly improves lichenification in patients with moderate to severe atopic dermatitis (AD) across all ages and racial backgrounds. Lichenification, characterized by skin thickening and a leathery appearance due to chronic scratching, is a hallmark of severe AD and often difficult to treat.
The study, which pooled data from 1,997 patients aged 6 to 88 years, assessed the efficacy of dupilumab compared to placebo in reducing lichenification. Improvements were observed as early as week 1 for adults and adolescents and week 2 for children, with sustained benefits through Week 16.
When analyzed by self-reported racial background, Asian, Black/African American, and White patients all experienced significant reductions in lichenification, highlighting dupilumab’s broad efficacy across diverse populations. The improvements were measured using multiple scoring systems, including SCORing Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI).
Dupilumab, a fully human monoclonal antibody, works by blocking interleukin (IL)-4 and IL-13 signaling, which drives type 2 inflammation. The study results reinforce dupilumab’s role in modulating epidermal hyperplasia and keratinocyte proliferation, key factors in chronic lichenified lesions.
These findings are particularly important for dermatologists and allergists treating patients with chronic, lichenified AD lesions, offering a proven treatment option that delivers early and sustained relief. Given that lichenification is more prevalent in patients of South-Eastern Asian or African descent, the study underscores the importance of ensuring access to effective therapies across all patient demographics.
With its ability to reduce lichenification rapidly and consistently, dupilumab remains a cornerstone treatment for moderate to severe AD, addressing not just inflammation but also chronic skin changes that impact patients’ quality of life.
Reference: Guttman-Yassky E et al. Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial Groups. J Drugs Dermatol. 2025;24(2):167-173.
Anaya Malik | AMJ
